QuidelOrtho CorpQDELEarnings & Financial Report
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Revenue
$711.0M
Gross Profit
N/A
Operating Profit
$-1.8B
Net Profit
$-1.7B
Gross Margin
N/A
Operating Margin
-247.3%
Net Margin
-239.9%
YoY Growth
-16.0%
EPS
$-25.50
Financial Flow
QuidelOrtho Corp Q1 2025 Financial Summary
QuidelOrtho Corp reported revenue of $711.0M (down 16.0% YoY) for Q1 2025, with a net profit of $-1.7B (down 3595.9% YoY) (-239.9% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $711.0M |
|---|---|
| Net Profit | $-1.7B |
| Gross Margin | N/A |
| Operating Margin | -247.3% |
| Report Period | Q1 2025 |
Revenue Breakdown
QuidelOrtho Corp Q1 2025 revenue of $711.0M breaks down across 5 segments, led by Labs at $356.9M (50.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Labs | $356.9M | 50.2% |
| Point Of Care | $186.6M | 26.2% |
| Transfusion Medicine | $160.3M | 22.5% |
| Molecular Diagnostics | $7.2M | 1.0% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $3.1M | 0.4% |
QuidelOrtho Corp Revenue by Segment — Quarterly Trend
QuidelOrtho Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Labs and Point Of Care) has evolved quarter over quarter.
| Segment | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 |
|---|---|---|---|---|
| Labs | $373.8M | $369.7M | $373.1M | $359.7M |
| Point Of Care | $164.6M | $93.0M | $170.8M | $184.8M |
| Molecular Diagnostics | $4.8M | $5.6M | $7.6M | $6.8M |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | $1.9M | $13.3M | $900.0K |
QuidelOrtho Corp Annual Revenue by Year
QuidelOrtho Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.8B).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.8B |
| 2024 | $3.0B |
QuidelOrtho Corp Quarterly Revenue & Net Profit History
QuidelOrtho Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 2026 | $699.9M | -3.7% | $-733.0M | -104.7% |
| Q2 2026 | $613.9M | -3.6% | $-255.4M | -41.6% |
| Q1 2026 | $692.8M | -2.6% | $-12.7M | -1.8% |
| Q4 2025 | $707.8M | -4.7% | $-178.4M | -25.2% |
| Q3 2025 | $727.1M | -2.3% | $-19.9M | -2.7% |
| Q2 2025 | $637.0M | -4.2% | $-147.7M | -23.2% |
| Q1 2025 | $711.0M | -16.0% | $-1.7B | -239.9% |
| Q4 2024 | $742.6M | — | $7.0M | 0.9% |
Income Statement
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $742.6M | $711.0M | $637.0M | $727.1M | $707.8M | $692.8M | $613.9M | $699.9M |
| YoY Growth | N/A | -16.0% | -4.2% | -2.3% | -4.7% | -2.6% | -3.6% | -3.7% |
Balance Sheet
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $8.56B | $6.70B | $6.69B | $6.80B | $6.42B | $6.46B | $6.38B | $5.68B |
| Liabilities | $3.56B | $3.40B | $3.52B | $3.61B | $3.44B | $3.46B | $3.59B | $3.64B |
| Equity | $5.01B | $3.31B | $3.17B | $3.19B | $2.98B | $3.00B | $2.79B | $2.04B |
Cash Flow
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $80.4M | $-700000 | $-97.9M | $117.9M | $63.7M | $65.6M | $-46.8M | $-45.5M |